Search Results for "gefitinib"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for gefitinib. Results 1 to 3 of 3 total matches.
See also: Iressa
Amivantamab (Rybrevant) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
[Tarceva], gefitinib [Iressa], and afatanib [Gilotrif]),
which are commonly used after platinum-based ...
Amivantamab-vmjw (Rybrevant – Janssen), an EGFR-MET
bispecific antibody, has received accelerated
approval from the FDA for IV treatment of locally
advanced or metastatic non-small cell lung cancer
(NSCLC) with epidermal growth factor receptor
(EGFR) exon 20 insertion mutations in adults whose
disease has progressed on or after platinum-based
chemotherapy. It is the first bispecific antibody
to become available in the US for this indication.
Accelerated approval of the drug was based on the
overall response rate and duration of response.
Table: Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
dipyridamole
elbasvir/grazoprevir
eltrombopag
eluxadoline
enasidenib
fostamatinib
fostemsavir
gefitinib ...
View the Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters tables
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e28-30 doi:10.58347/tml.2023.1669g | Show Introduction Hide Introduction
Mobocertinib (Exkivity) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
inhibitors (erlotinib
[Tarceva], gefitinib [Iressa], afatanib [Gilotrif]),
which are commonly used after ...
Mobocertinib (Exkivity – Takeda), an oral kinase
inhibitor, has received accelerated approval from the
FDA for treatment of locally advanced or metastatic
non-small cell lung cancer (NSCLC) with epidermal
growth factor receptor (EGFR) exon 20 insertion
mutations in adults whose disease has progressed on
or after platinum-based chemotherapy. Accelerated
approval was based on the overall response rate and
duration of response. Mobocertinib is the second
drug to become available in the US for this indication;
the IV EGFR-MET bispecific antibody amivantamab
(Rybrevant) was approved...